Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends

Ticker	Company	Market Cap	Dividend Yield	Payout Ratio	Last Dividend	Annual Dividend	Dividend Percentile	Dividend Dropped Count (L10Y)	Ex-dividend Date	Div. Payment Date
FONR	FONAR CORP	$109.45M	N/A	0.00%	N/A	N/A	N/A	N/A
ICLR	ICON PLC	$25.55B	N/A	0.00%	N/A	N/A	N/A	N/A
STRR	STAR EQUITY HOLDINGS INC	$14.26M	N/A	0.00%	$0.5500	N/A	N/A	0
RVTY	REVVITY INC	$12.43B	0.28%	5.00%	$0.0700	$0.28	3%	0	2024-07-19	2024-05-10
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$11.99B	N/A	0.00%	N/A	N/A	N/A	N/A
NEOG	NEOGEN CORP	$2.60B	N/A	0.00%	N/A	N/A	N/A	N/A
IDXX	IDEXX LABORATORIES INC	$39.69B	N/A	0.00%	N/A	N/A	N/A	N/A
TMO	THERMO FISHER SCIENTIFIC INC	$218.49B	0.25%	9.20%	$0.3900	$1.44	3%	0
ENZ	ENZO BIOCHEM INC	$53.27M	N/A	0.00%	N/A	N/A	N/A	N/A
A	AGILENT TECHNOLOGIES INC	$40.87B	0.66%	21.60%	$0.2360	$0.92	11%	1
QGEN	QIAGEN NV	$9.62B	2.98%	87.20%	$1.2800	$1.28	55%	0
DGX	QUEST DIAGNOSTICS INC	$15.26B	2.10%	38.20%	$0.7500	$2.88	42%	0
SHC	SOTERA HEALTH CO	$3.12B	N/A	0.00%	N/A	N/A	N/A	N/A
DHR	DANAHER CORP	$183.97B	0.42%	17.60%	$0.2700	$1.05	6%	2
MEDP	MEDPACE HOLDINGS INC	$12.16B	N/A	0.00%	N/A	N/A	N/A	N/A
WAT	WATERS CORP	$19.02B	N/A	0.00%	N/A	N/A	N/A	N/A
LH	LABORATORY CORP OF AMERICA HOLDINGS	$16.97B	1.43%	56.50%	$0.7200	$2.88	28%	0	2024-05-28	2024-06-12
MTD	METTLER TOLEDO INTERNATIONAL INC	$26.89B	N/A	0.00%	N/A	N/A	N/A	N/A
FLGT	FULGENT GENETICS INC	$643.37M	N/A	0.00%	N/A	N/A	N/A	N/A
SERA	SERA PROGNOSTICS INC	$351.82M	N/A	0.00%	N/A	N/A	N/A	N/A
CSTL	CASTLE BIOSCIENCES INC	$671.68M	N/A	0.00%	N/A	N/A	N/A	N/A
PRE	PRENETICS GLOBAL LTD	$63.83M	N/A	0.00%	N/A	N/A	N/A	N/A
IQV	IQVIA HOLDINGS INC	$40.70B	N/A	0.00%	N/A	N/A	N/A	N/A
NTRA	NATERA INC	$11.71B	N/A	0.00%	N/A	N/A	N/A	N/A
PSNL	PERSONALIS INC	$77.78M	N/A	0.00%	N/A	N/A	N/A	N/A
PRPO	PRECIPIO INC	$8.30M	N/A	0.00%	N/A	N/A	N/A	N/A
DRIO	DARIOHEALTH CORP	$46.22M	N/A	0.00%	N/A	N/A	N/A	N/A
OLK	OLINK HOLDING AB (PUBL)	$2.86B	N/A	0.00%	N/A	N/A	N/A	N/A
ACRS	ACLARIS THERAPEUTICS INC	$96.46M	N/A	0.00%	N/A	N/A	N/A	N/A
NEO	NEOGENOMICS INC	$1.95B	N/A	0.00%	N/A	N/A	N/A	N/A
DMTK	DERMTECH INC	$21.78M	N/A	0.00%	N/A	N/A	N/A	N/A
TWST	TWIST BIOSCIENCE CORP	$2.40B	N/A	0.00%	N/A	N/A	N/A	N/A
STIM	NEURONETICS INC	$113.37M	N/A	0.00%	N/A	N/A	N/A	N/A
EXAS	EXACT SCIENCES CORP	$11.27B	N/A	0.00%	N/A	N/A	N/A	N/A
BGLC	BIONEXUS GENE LAB CORP	$10.67M	N/A	0.00%	N/A	N/A	N/A	N/A
RDNT	RADNET INC	$3.51B	N/A	0.00%	N/A	N/A	N/A	N/A
OCX	ONCOCYTE CORP	$22.01M	N/A	0.00%	N/A	N/A	N/A	N/A
BNR	BURNING ROCK BIOTECH LTD	$82.67M	N/A	0.00%	N/A	N/A	N/A	N/A
APDN	APPLIED DNA SCIENCES INC	$3.18M	N/A	0.00%	N/A	N/A	N/A	N/A
LAB	STANDARD BIOTOOLS INC	$728.20M	N/A	0.00%	N/A	N/A	N/A	N/A
XGN	EXAGEN INC	$24.13M	N/A	0.00%	N/A	N/A	N/A	N/A
XWEL	XWELL INC	$7.49M	N/A	0.00%	N/A	N/A	N/A	N/A
GH	GUARDANT HEALTH INC	$2.30B	N/A	0.00%	N/A	N/A	N/A	N/A
CDNA	CAREDX INC	$503.29M	N/A	0.00%	N/A	N/A	N/A	N/A
BDSX	BIODESIX INC	$135.72M	N/A	0.00%	N/A	N/A	N/A	N/A
CHEK	CHECK-CAP LTD	$12.87M	N/A	0.00%	N/A	N/A	N/A	N/A
ME	23ANDME HOLDING CO	$242.42M	N/A	0.00%	N/A	N/A	N/A	N/A
ULS	UL SOLUTIONS INC	N/A	N/A	0.00%	N/A	N/A	N/A	N/A
PRPH	PROPHASE LABS INC	$97.81M	N/A	0.00%	$0.3000	N/A	N/A	0
NDRA	ENDRA LIFE SCIENCES INC	$3.61M	N/A	0.00%	N/A	N/A	N/A	N/A
OPK	OPKO HEALTH INC	$906.09M	N/A	0.00%	N/A	N/A	N/A	N/A
NOTV	INOTIV INC	$110.13M	N/A	0.00%	N/A	N/A	N/A	N/A
AWH	ASPIRA WOMEN's HEALTH INC	$39.62M	N/A	0.00%	N/A	N/A	N/A	N/A
MDXH	MDXHEALTH SA	$8.57M	N/A	0.00%	N/A	N/A	N/A	N/A
VNRX	VOLITIONRX LTD	$73.12M	N/A	0.00%	N/A	N/A	N/A	N/A
GENE	GENETIC TECHNOLOGIES LTD	$520.53k	N/A	0.00%	N/A	N/A	N/A	N/A
ISPC	ISPECIMEN INC	$2.39M	N/A	0.00%	N/A	N/A	N/A	N/A
MYGN	MYRIAD GENETICS INC	$1.75B	N/A	0.00%	N/A	N/A	N/A	N/A
BIAF	BIOAFFINITY TECHNOLOGIES INC	$24.07M	N/A	0.00%	N/A	N/A	N/A	N/A
ILMN	ILLUMINA INC	$18.79B	N/A	0.00%	N/A	N/A	N/A	N/A
PMD	PSYCHEMEDICS CORP	$14.64M	2.75%	-19.40%	$0.0700	$0.07	51%	1
TRIB	TRINITY BIOTECH PLC	$13.81M	N/A	0.00%	$1.1000	N/A	N/A	0
MYNZ	MAINZ BIOMED NV	$15.60M	N/A	0.00%	N/A	N/A	N/A	N/A
MMA	ALTA GLOBAL GROUP LTD	N/A	N/A	0.00%	N/A	N/A	N/A	N/A
CNTG	CENTOGENE NV	$12.22M	N/A	0.00%	N/A	N/A	N/A	N/A
TTOO	T2 BIOSYSTEMS INC	$20.51M	N/A	0.00%	N/A	N/A	N/A	N/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 3.69% over the past year, overperforming other diagnostic & research stocks by 4 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second best diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 66.35% over the past year, overperforming other diagnostic & research stocks by 67 percentage points.

Icon has an average 1 year price target of $344.38, an upside of 11.44% from Icon's current stock price of $309.02.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Icon, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the third best diagnostic & research stock with a Zen Score of 46, which is 19 points higher than the diagnostic & research industry average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 37.4% over the past year, overperforming other diagnostic & research stocks by 38 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 2.98%, which is 2 percentage points higher than the diagnostic & research industry average of 1.36%.

Qiagen Nv's dividend payout ratio of 87.2% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.1%, which is 1 percentage points higher than the diagnostic & research industry average of 1.36%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.2% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)

Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.43%, which is the same as the diagnostic & research industry average of 1.36%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 56.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.85% in the last day, and up 0.7% over the last week. Twist Bioscience was the among the top gainers in the diagnostics & research industry, gaining 28.74% yesterday.

Twist Bioscience shares are trading higher after the company reported better-than-expected Q2 financial results.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 52 points higher than the diagnostic & research industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 37.4% in the past year. It has overperformed other stocks in the diagnostic & research industry by 38 percentage points.

2. Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 52 points higher than the diagnostic & research industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -59.85% in the past year. It has underperformed other stocks in the diagnostic & research industry by -59 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 52 points higher than the diagnostic & research industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 3.69% in the past year. It has overperformed other stocks in the diagnostic & research industry by 4 percentage points.

Are diagnostic & research stocks a good buy now?

52.08% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 10.51% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 38.44x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.